Saxagliptin
$8.00
Universal Activity Number: 407-000-10-057-H01-T
CEUs 1.0
Audience: Pharmacy Technicians
Activity Type: Knowledge-based
Issued date: 05/01/2010
Expiration date: 05/01/2013
Submit your answers by clicking here
completed purchase is required to receive the corresponding CEUs.
CEUs 1.0
Audience: Pharmacy Technicians
Activity Type: Knowledge-based
Issued date: 05/01/2010
Expiration date: 05/01/2013
Submit your answers by clicking here
completed purchase is required to receive the corresponding CEUs.
Article title:
Saxagliptin: New Therapy for Type 2 Diabetes
Goal
Information regarding the disease of diabetes mellitus, therapeutic goals for treatment, and treatment algorithms is reviewed. A new treatment option for type 2 diabetes mellitus, saxagliptin, is discussed, with emphasis on its place in therapy. The pharmacy technician is given the current information available for saxagliptin to help the technician better understand the use of saxagliptin for the treatment of diabetes mellitus.
Objectives
Upon completion of this CE article, the pharmacy technician
will be able to:
-
Distinguish between type 1 and type 2 diabetes mellitus and the available therapies for each.
-
Understand the meaning of A1C.
-
Understand the results of the different trials involving saxagliptin.
- Know the dosage forms of saxagliptin available and when each might be used.
Abstract
Objective: To evaluate the efficacy of saxagliptin for the treatment of hyperglycemia associated with type 2 diabetes.
Data Sources: A MEDLINE/PubMed search was conducted of all available date ranges from 1990 through October 2009 for literature in the English language, using the search terms saxagliptin, type 2 diabetes mellitus, incretin hormones, and dipeptidyl peptidase-4 inhibitors. The manufacturer of saxagliptin (Onglyza) was contacted for clinical trial information.
Study Selection: Five prospective, randomized controlled trials were reviewed. Studies were included in this review if they had examined saxagliptin and its effects on hyperglycemia. Trials examined included those on saxagliptin monotherapy and those on
saxagliptin in combination with metformin, with a sulfonylurea, and with a thiazolidinedione. Data from the MEDLINE/PubMed search, as well as clinical trial data obtained from the manufacturer, were used in this review.
saxagliptin in combination with metformin, with a sulfonylurea, and with a thiazolidinedione. Data from the MEDLINE/PubMed search, as well as clinical trial data obtained from the manufacturer, were used in this review.
Data Synthesis: Saxagliptin demonstrated statistically significant decreases of 0.43–0.54% in hemoglobin A1c (A1C) in the monotherapy treatment group. The A1C-lowering effects were the greatest, with a decrease of 2.5% in patients concomitantly
administered metformin and saxagliptin as initial therapy. In addition to its effects on A1C, saxagliptin proved to be weight neutral and had minimal risks of hypoglycemia, with hypoglycemia seen only in the saxagliptin in combination with a sulfonylurea group.
administered metformin and saxagliptin as initial therapy. In addition to its effects on A1C, saxagliptin proved to be weight neutral and had minimal risks of hypoglycemia, with hypoglycemia seen only in the saxagliptin in combination with a sulfonylurea group.
Conclusions: Saxagliptin is an effective treatment for hyperglycemia associated with type 2 diabetes. It is currently a third-line option in the American Diabetes Association treatment algorithm for type 2 diabetes and, based on the trials reviewed here, this is an
acceptable place in therapy. Saxagliptin is a good option for patients with diabetes who are at high risk of hypoglycemia.
acceptable place in therapy. Saxagliptin is a good option for patients with diabetes who are at high risk of hypoglycemia.
J Pharm Technol 2010;26:123-8.